New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™ Test
November 20, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium
November 17, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Participate in the 32nd Annual Piper Sandler Healthcare Conference
November 16, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Host Preeclampsia Virtual R&D Day on November 20, 2020
November 13, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Provides Corporate Updates and Reports Third Quarter 2020 Financial Results
November 09, 2020 16:05 ET
|
Progenity, Inc.
Reported 84 thousand tests in the third quarter, up 12% compared to the second quarter Achieved a preeclampsia test analytical verification milestone Management will host conference call and webcast...
Progenity Announces Encouraging Preclinical Data Supporting the Potential of the Company’s Oral Drug Delivery System in Targeting the Colon
November 06, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update
November 03, 2020 08:43 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Successful Achievement of its Preeclampsia Test Analytical Verification Milestone
October 29, 2020 07:30 ET
|
Progenity, Inc.
Announces Expansion of its COVID-19 Testing Offering Provides Preliminary Third Quarter 2020 Financial Update SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a...
Non-Invasive Prenatal Testing (NIPT) Market Size to Surpass US$ 11 billion by 2030
October 28, 2020 17:30 ET
|
insightSLICE
PUNE, India, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The Global Non-Invasive Prenatal Testing (NIPT) Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business...
Progenity Presents Data from Award-Winning Abstract on Novel Ingestible Lab-in-a-Capsule at American College of Gastroenterology (ACG) 2020 Virtual Annual Meeting
October 27, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...